

FIG 1




FIG 2




FIG 3







FIG 4




**BRI6727**




**BRI6728**



**BRI6734**




**BRI6813**




**BRI6795**


**FIG 5A**




**BRI6796**




**BRI6797**



**BRI6798**




**BRI6799**




**BRI6800**


**FIG 5B**




BRI6801




BRI6802



BRIX114



BRI6803



BRI6814

FIG 5C






FIG 5D







BRI6824




BRI6825



BRI6829




BRI6855




BRI6856

FIG 5E






BRI7009



BRI7012


FIG 5G



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as Indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

**FIG 6**


# Inhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 7


# Inhibition or enhancement of FcγRIIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 8

Finhibition or enhancement of FcγRIIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 9

# Enhanced sFcγRII binding





FIG 10



Inhibition of sFcγRIIIa binding




FIG 11



Activation of platelets in the presence of agonist only.  
Platelets ( $100 \times 10^6/\text{ml}$ ) were mixed in the presence of Fc $\gamma$ RIIa agonist (HAGG,  $200 \mu\text{g}/\text{ml}$ ) and PBS and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 12



Activation of platelets in the presence of agonist and BRI compound 6855.  
Platelets ( $100 \times 10^6/\text{ml}$ ) were mixed in the presence of Fc $\gamma$ R1a agonist (HAGG,  $200 \mu\text{g}/\text{ml}$ ) and compound BRI 6855 ( $5 \text{ mg}/\text{ml}$ ) and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 13

Effect of BRI compound 6728 on platelet aggregation with HAGG




FIG 14